Seeking Alpha

Sanofi-Aventis (SNY -2%) settles more patent infringement suits over its cancer drug Eloxatin,...

Sanofi-Aventis (SNY -2%) settles more patent infringement suits over its cancer drug Eloxatin, this time with Mayne Pharma (HSP), Par Pharmaceutical (PRX) and Iceland's Actavis. The firms will stop selling unauthorized versions of Eloxatin in the U.S. between June 30, 2010 and Aug. 9, 2012, which should boost Sanofi's sales.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|